The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia

QJM: An International Journal of Medicine

Volumn 89, Issue 8, 1996, Pages 571-577

  Harmon, D L ^a   Woodside, J V ^b   Yarnell, J W G ^b   McMaster, D ^b   Young, I S ^b   McCrum, E E ^b   Gey, K F ^c   Whitehead, A S ^a   Evans, A E ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; DIET SUPPLEMENTATION; FOLIC ACID BLOOD LEVEL; GENE FUNCTION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOCYSTINURIA; HOMOZYGOSITY; HUMAN; MALE; NEURAL TUBE DEFECT; NORMAL HUMAN; NUTRITIONAL DEFICIENCY; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE; VITAMIN BLOOD LEVEL;

EID: 0029738540     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.8.571     Document Type: Article

References (31)

1. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877-81.
2. Genest JJ, Jr, McNamara JR, Salem DN, Wilson PWF, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16:1114-19.
3. Molgaard J, Malinow MR, Lassvik C, Holm A-C, Upson B, Olsson AG. Hyperhomocyst(e)inaemia: an independent risk factor for intermittent claudication. J Intern Med 1992; 231:273-9.
4. Taylor LM, Jr, DeFrang RD, Harris E, Jr, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13:128-36.
5. Brattstrom L, Lindgren A, Israelsson B, Malinow MR, Norrving B, Upson B, Hamfelt A, Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. EurJ Clin Invest 1992; 22:214-21.
6. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79:1180-8.
7. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345:882-5.
8. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345:149-51.
9. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 1989:693-734.
10. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, McGraw-Hill, 1989:2049-64.
11. Kang S-S, Zhou JZ, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-21.
12. Kang S-S, Wong PWK, Zhou J, Sora J, Lessick M, Ruggie N, Grcevich G. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 1988; 37:611-13.
13. Kang S-S, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genef 1991; 48:536-45.
14. Kang S-S, Passen EL, Ruggie N, Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993; 88:1463-9.
15. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels FJM, Blom HK. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56:142-50.
16. Goyette P, Sumner JS, Milos R, Duncan AMV, Rosenblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nature Genet 1994; 7:195-200.
17. Goyette P, Frosst P, Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and geneotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56:1052-9.
18. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10:111-13.
19. Kluitjmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinaemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.
20. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC, Scott JM. A genetic defect in 5,10-methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995; 88:763-6.
21. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, Mariman ECM, den Heyer M, Rozen R, Blom HJ. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-1.
22. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by HPLC with fluorescence detection. J Chromatogr 1987; 422:43-52.
23. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high-performance liquid Chromatographic assay for total homocysteine levels in human serum. J Chromatogr 1991; 565:441-6.
24. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-8.
25. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.
26. Lucock MD, Wild J, Schorah CJ, Levene MI, Hartley R. The methylfolate axis in neural tube defects: In Vitro characterisation and clinical investigation. Biochem Med Metab Biol 1994;52:101-14.
27. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptual vitamin supplementation. N Engl J Med 1992; 327:1832-5.
28. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991; 338:131-7.
29. Brattstrom LE, Israelsson B, Jeppsson J-O, Hultberg BL. Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Lab Clin Invest 1988; 48:215-21.
30. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Int Med 1995; 237:381-8.
31. Brattstrom L, Israelsson B, Norrvig B, Bergqvist D, Thorne J, Hultberg B, Hamfelt A. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Atherosclerosis 1990; 81:51-60.